Search

everythinglearnresearchcommunity

for

Search:↓

Dupilumab and ustekinumab are promising treatments for alopecia areata, showing significant hair regrowth.

Testosterone therapy significantly improved Hidradenitis Suppurativa symptoms.

Dupilumab may worsen Alopecia Areata in some males but improve it in some females, suggesting personalized treatment is needed.

In 2024, the FDA approved 50 new drugs, including treatments for hair loss, anemia, high blood pressure, and Alzheimer's.

The ILDS Newsletter reported on efforts to support albinism patients in Tanzania and dermatological conferences.

Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.

The choice between belimumab and anifrolumab depends on the specific symptoms of the patient's lupus.

Anifrolumab improves quality of life and reduces steroid use in SLE patients.

The choice between belimumab and anifrolumab for treating lupus depends on the patient's specific symptoms.

Selective immunotherapies like anifrolumab and belimumab are more effective for treating systemic lupus erythematosus than traditional drugs.

Anifrolumab improves quality of life and reduces steroid use in lupus patients.

Lupus patients in Ghana face healthcare challenges, and the Oyemam Autoimmune Foundation is working to improve awareness and support.

Anifrolumab effectively improved symptoms and reduced steroid use in Japanese patients with systemic lupus erythematosus.

Safusidenib erbumine shows promise as a treatment for certain brain tumors, but mild side effects like hair loss need attention.

Dupilumab is being tested for many new skin, respiratory, and gastrointestinal conditions.

INTASYL is a promising, adaptable RNAi technology for treating skin cancers.

Anifrolumab treatment improves quality of life and reduces disease activity and steroid use in SLE patients.

People with lupus in Mauritius face many challenges and need more support and understanding.

Kūlaris improved quality of life for acne sufferers without side effects.

Ixekizumab helps improve life quality, physical ability, and work performance in patients with psoriatic arthritis who haven't used biologic drugs before.

Anifrolumab may help improve symptoms in patients with overlapping autoimmune diseases.

Belimumab effectively controls SLE disease activity and reduces steroid use.

IVL-DrugFluidic® can mass-produce high-quality, long-acting injectable drug microspheres, improving patient compliance and reducing side effects.

The drug Olumiant is now approved to treat severe hair loss from alopecia and can also be used for some hospitalized COVID-19 patients.

Uveal melanoma is hard to treat when it spreads, but a new drug, tebentafusp, helps patients live longer.

IV cyclophosphamide effectively treated severe lupus nephritis in Indian patients.

Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.

Lupus severely affects daily life, work, and mental health, with many experiencing frequent flares and medication side-effects.

New treatments for lupus show promise, but more research is needed, especially for children.

Ipilimumab can cause various adverse events in elderly patients, especially affecting the gastrointestinal and endocrine systems.